Cargando…

PCSK9 inhibition: the way forward in the treatment of dyslipidemia

Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stoekenbroek, Robert M., Kastelein, John JP, Huijgen, Roeland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601145/ https://www.ncbi.nlm.nih.gov/pubmed/26456772 http://dx.doi.org/10.1186/s12916-015-0503-4

Ejemplares similares

PCSK9 Gene Participates in the Development of Primary Dyslipidemias
por: Matías-Pérez, D, et al.
Publicado: (2021)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015)

PCSK9 Inhibition: From Current Advances to Evolving Future
por: Liu, Chunping, et al.
Publicado: (2022)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
por: Kawakami, Ryo, et al.
Publicado: (2018)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
por: Kastelein, John J.P., et al.
Publicado: (2016)

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
por: Sliz, Eeva, et al.
Publicado: (2018)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
por: Päth, Günter, et al.
Publicado: (2022)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

PCSK9 inhibition in high-risk patients
por: Zijlstra, Laurien E., et al.
Publicado: (2019)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
por: Du, Ying, et al.
Publicado: (2016)

Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
por: Huijgen, Roeland, et al.
Publicado: (2010)

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
por: Huang, Hui-Chun, et al.
Publicado: (2022)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
por: Leucker, Thorsten M., et al.
Publicado: (2020)

PCSK9 Biology and Its Role in Atherothrombosis
por: Barale, Cristina, et al.
Publicado: (2021)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

PCSK9 and the nervous system: a no-brainer?
por: Jaafar, Ali K., et al.
Publicado: (2023)

Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection
por: Chin, Kai Ling, et al.
Publicado: (2023)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
por: Sobati, Saeideh, et al.
Publicado: (2020)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
por: Zeitlinger, Markus, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i7bavefefmf1f8r0g8faq32iin